Navigation Links
Microfluidic technology reveals potential biomarker for early pancreatic cancer
Date:4/29/2014

ANN ARBOR, Mich. Cancer cells are on the move in the bloodstream in the very early stage of pancreatic cancer, and can be detected before cancer is diagnosed, according to research by the University of Michigan Health System.

In a study of 51 patients, researchers used a state-of-the art microfluidic device to capture circulating pancreas epithelial cells in 33 percent of patients with early pancreatic lesions and no clinical diagnosis of cancer.

The findings, published in Gastroenterology, suggest that circulating pancreas cells (CPCs) seed the bloodstream before tumors can be detected using current clinical tests such as CT and MRI scans. The data suggest that the detection of pancreas cells in the blood may be an early sign of cancer.

"While there is much work that still needs to be done, there is great potential for using this technology to identify who is most at risk for developing pancreatic cancer," says lead author Andrew Rhim, M.D., an assistant professor of internal medicine at the U-M Health System and gastroenterologist at the U-M Comprehensive Cancer Center's Multidisciplinary Pancreatic Cancer Clinic.

One reason the outlook for pancreatic cancer is poor is that very few of the cancers are found early. Patients usually have no symptoms until the cancer has spread to other organs. There are no blood tests to find early cancers of the pancreas.

It is thought that cancer cells seed the bloodstream late in cancer progression, when large tumors are present. But based on studies in animal models of pancreatic cancer, U-M researchers and colleagues theorized that dissemination happens before we tumors can be detected.

They studied three groups of patients: those who were cancer-free, those diagnosed with precancerous cystic lesions, and patients with pancreatic cancer. Researchers captured circulating epithelial cells in 73 percent of patients with cancer. None of the 19 cancer-free patients without lesions had these cells in their bloodstream.

"Studies are underway to interrogate the genomic signature of circulating pancreas cells from patients with precancerous cystic lesions," says Rhim.

"If these cells represent the earliest forms of cancer, we predict they would possess many of the genetic anomalies we typically see in pancreas tumors."


'/>"/>

Contact: Shantell M. Kirkendoll
smkirk@umich.edu
734-764-2220
University of Michigan Health System
Source:Eurekalert  

Related medicine news :

1. Microfluidics Market to Grow at a CAGR of 17.6% to 2018 Forecasts in New Research Report at RnRMarketResearch.com
2. Microfluidics Market Worth $3.5 Billion by 2018
3. Mechanical tissue resuscitation technology shows promise
4. New study identifies how information technology is used to solve global health challenges
5. Power generation technology based on piezoelectric nanocomposite materials developed by KAIST
6. Simulation technology allows users to safely practice phacoemulsification cataract surgery
7. The Casey Group's Sales Navigator Wins 2012 Best Mobility App in the New Jersey Technology Council's Mobile Application Competition
8. Swanson Health Products Introduces a New Alkalizing Drink Mix, Swanson® pH Balance Alka-Tone with Alka-Plex™ Technology
9. Miami Children’s Hospital Performs First Nerve Repair Surgery Using Avance® Nerve Graft Technology
10. FDA Approves SonixGPS Needle Guidance Technology for Vascular Access Procedures
11. IVR Technology Group Named Platimum VAR by TSYS
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Microfluidic technology reveals potential biomarker for early pancreatic cancer
(Date:2/27/2017)... ... February 27, 2017 , ... POUGHKEEPSIE, N. Y. – Peer-reviewed guidelines from the ... studies, the Center for Disease Control ( CDC ) and Infectious Diseases Society of ... Liegner, M.D. has compiled into a single volume a compelling argument that the disease ...
(Date:2/27/2017)... ... February 27, 2017 , ... Sunshine Coast ... in British Columbia, Canada, at https://www.sunshinecoasthealthcentre.ca/ , is proud to announce the ... Mackenzie Alsager, showcases the Centre's commitment to innovation in drug rehab and alcohol ...
(Date:2/27/2017)... ... February 27, 2017 , ... Silicon Valley Hair Institute, ... announce an upgrade to the company's Yelp listing. Bay Area residents struggling from ... diverse as Platelet Rich Plasma (PRP) therapy, hair transplantation techniques such as Follicular ...
(Date:2/26/2017)... MICHIGAN (PRWEB) , ... February 25, 2017 , ... The ... Kim Jong-un, heightened awareness and concern over nerve agents and the deadly use of ... the human nervous system and how even small doses can be lethal. , Jay ...
(Date:2/26/2017)... ... February 26, 2017 , ... ... lab became the world’s first to be ISO/IEC 17025:2005 INAB accredited for Der ... , ISO/IEC 17025:2005 is the globally recognised standard that sets out requirements for ...
Breaking Medicine News(10 mins):
(Date:2/24/2017)... 23, 2017  The particle counters market is ... from USD 275.9 million in 2016, at a ... report: http://www.reportlinker.com/p04718602-summary/view-report.html The growing ... R&D, and growth in manufacturing industries in emerging ... for particle counters. On the other hand, technical ...
(Date:2/24/2017)... -- Research and Markets has announced the addition of ... report to their offering. ... The latest research Urinary Incontinence Drugs Price Analysis ... the global Urinary Incontinence market. The research answers the following ... marketed for Urinary Incontinence and their clinical attributes? How are they ...
(Date:2/23/2017)... YORK , Feb. 23, 2017  Genesis Healthcare ... Company. The announcement was made by Bill Monast ... David Hartley and Nathan Feltman , executives ... Genesis Healthcare Services, LLC. This acquisition ... largest provider of technology enabled durable medical equipment (DME) ...
Breaking Medicine Technology: